drugset / Trial / NCT00311350

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

NCT00311350

Phase 1 Completed 48 enrolled Bausch Health Americas, Inc.
RandomizedDouble-blind

Summary

This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Timeline

Start
2006-03
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified Oral

Indications